|
MechanismM1 receptor antagonists [+1] |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date17 Mar 2020 |
|
MechanismDopamine reuptake inhibitors [+2] |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
苯环喹溴铵吸入气雾剂单次给药人体药代动力学和药效学临床试验
[Translation] Pharmacokinetics and Pharmacodynamics Clinical Trial of Bencycloquinium Bromide Inhalation Aerosol Single-dose in Humans
观察单次给予慢性阻塞性肺疾病(COPD)患者苯环喹溴铵吸入气雾剂的药代动力学及药效学特点,为制定Ⅱ期临床试验给药方案提供依据
[Translation] To observe the pharmacokinetics and pharmacodynamics of a single dose of benzoquinium bromide inhalation aerosol in patients with chronic obstructive pulmonary disease (COPD), and to provide evidence for the formulation of the drug regimen for phase II clinical trials
[Translation] Pharmacokinetic Clinical Trial of Bencycloquinium Bromide Inhalation Aerosol
观察单次和连续给予健康受试者苯环喹溴铵吸入气雾剂的药代动力学特点,为制定Ⅱ期临床试验给药方案提供依据。
[Translation] To observe the pharmacokinetic characteristics of phencycloquinium bromide inhalation aerosol administered to healthy subjects in a single and continuous time, to provide a basis for formulating the dosing scheme of phase II clinical trials.
[Translation] Tolerability clinical trial of benzoquinium bromide inhalation aerosol
观察单次和连续给予健康受试者苯环喹溴铵吸入气雾剂的安全性和耐受性,评估苯环喹溴铵吸入气雾剂的安全剂量范围,确定人体最大耐受量,为制定Ⅱ期临床试验给药方案提供依据。
[Translation] To observe the safety and tolerability of single and continuous administration of benzoquinium bromide inhalation aerosol to healthy subjects, to evaluate the safe dose range of benzoquinium bromide inhalation aerosol, and to determine the maximum tolerated dose in humans, which is Provide the basis for the formulation of the dosing regimen for phase II clinical trials.
100 Clinical Results associated with Beijing Jiashi Lianbo Medicine Technology Co Ltd
0 Patents (Medical) associated with Beijing Jiashi Lianbo Medicine Technology Co Ltd
100 Deals associated with Beijing Jiashi Lianbo Medicine Technology Co Ltd
100 Translational Medicine associated with Beijing Jiashi Lianbo Medicine Technology Co Ltd